Skip to main content

Table 2 Baseline demographic, clinical and radiographic characteristics of the patients included in assessment of the radiographic progression in this study.

From: Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?

Assessment N= 195*
Age (years) 42.8 (12.4)
Male gender (%) 138 (71%)
HLA-B27 positive (%) 158 (84%)
Symptoms duration (years) 20.4 (12.9)
Disease duration (years) 11.0 (8.7)
ASDAS-CRP 2.7 (1.0)
BASDAI (0-10) 3.4 (2.0)
BASFI (0-10) 3.2 (2.5)
BASMI (0-10) 3.7 (1.5)
CRP (mg/l) (N = 186) 17.5 (23.5)
Elevated CRP (%)‡ 96 (52%)
mSASSS (0-72) (N = 177)¥ 10.8 (15.2)
RASSS (0-84) (N = 130) 11.8 (16.6)
mSASSS of patients with available RASSS (0-72) (N = 130) 10.1 (14.2)
mSASSS > 0 (%) (N = 177) 143 (81%)
RASSS > 0 (%) (N = 130) 107 (82%)
mSASSS > 0 of patients with available RASSS (%) (N = 130) 106 (82%)
  1. *Data are presented as mean (SD) or n (%). N = 195, representing patients with ≥ 1 radiograph with the mSASSS evaluable throughout follow-up (not necessarily at baseline available). ‡The cutoff was 10 mg/l for the Dutch patients (n = 122) and 5 mg/l for the Belgian (n = 23) and French patients (n = 50); ¥18 patients did not have a radiograph with an mSASSS evaluable at baseline, but had a radiograph in which the mSASSS could be calculated at a later time point and were therefore included in the study. ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score (C-reactive protein); BASDAI, Bath Ankylosing Spondylitis Disease Activity Score; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; RASSS, radiographic Ankylosing Spondylitis Spinal Score.